antibody-drug conjugate development

Antigenix Therapeutics Inc, a Syridex Bio Company, is a biotechnology company developing antibody-based therapies, including antibody-drug conjugate (ADC) therapies, for cancers resistant to current treatments. Its patented antibody technology targets a cancer-specific marker to attack tumors while sparing healthy cells. The company develops monoclonal antibody-based therapies targeting novel, tumor-specific cell surface proteins and is preparing a pre-clinical program toward IND submission.

Read more

biotech venture creationclinical advancementpre-clinical program developmenttranslational medicine

BiFormyx BioPharma is a biopharma company developing dual-payload antibody-drug conjugates (DualADCs) to treat aggressive solid tumors such as TNBC with precision and potency. Its DualADC platform delivers two distinct therapeutic payloads (e.g., cytotoxic and immunomodulatory) directly to cancer cells using proprietary linker combinations and tumor-specific targeting moieties.

Read more

proprietary linker combinationstumor-specific targeting moieties